Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 3,828 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 3,828 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $18.10, for a total transaction of $69,286.80. Following the completion of the transaction, the chief operating officer directly owned 210,164 shares in the company, valued at approximately $3,803,968.40. The trade was a 1.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.02, for a total transaction of $2,684.98.
• On Monday, December 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.68, for a total transaction of $233,500.00.
• On Friday, November 21st, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.05, for a total transaction of $225,625.00.

Bicara Therapeutics Stock Performance

Shares of BCAX stock traded down $0.32 during mid-day trading on Monday, reaching $16.42. 567,617 shares of the company’s stock traded hands, compared to its average volume of 484,589. The firm has a market capitalization of $899.49 million, a PE ratio of -7.33 and a beta of -0.79. Bicara Therapeutics Inc. has a 12 month low of $7.80 and a 12 month high of $19.71. The firm has a 50 day moving average price of $17.45 and a two-hundred day moving average price of $14.72.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.12). As a group, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds have recently modified their holdings of BCAX. Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics during the fourth quarter valued at $45,000. Legal & General Group Plc lifted its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after purchasing an additional 1,474 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BCAX. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Finally, BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.